The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase I study of KITE-753 or KITE-363 in patients with R/R B-cell lymphoma
Saurabh Dahiya, MD, FACP, Stanford University School of Medicine, Stanford, CA, discusses the results of a Phase I study (NCT04989803) investigating KITE-753 and KITE-363 in patients with relapsed/refractory (R/R) B-cell lymphoma, highlighting the updated data for KITE-363 and the preliminary results of KITE-753. Both products demonstrated encouraging efficacy in a high-risk patient population, and Dr Dahiya notes that plans are underway to move these trials to registrational studies in the large B-cell lymphoma (LBCL) setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
